Our results showed that the RHOA mutation had a favorable prognosis for EBV+ DLBCL, which provided a new perspective for the research of RHOA. However, our predictive results were limited by the small sample size and required further large cohorts validations. The gene discussed is RHOA; the disease is diffuse large B-cell lymphoma.